



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Latanoprostene Bunod

Item No. 25830

CAS Registry No.: 860005-21-6
Formal Name: (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid, 4-(nitrooxy)butyl ester
Synonyms: BOL-303259-X, NCX 116, PF-3187207
MF: C₂₇H₄₁NO₈
FW: 507.6
Purity: ≥95%
Supplied as: A solution in ethanol
Storage: -20°C
Stability: ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Latanoprostene bunod is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of latanoprostene bunod in these solvents is approximately 30 mg/ml.

Latanoprostene bunod is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the ethanolic solution of latanoprostene bunod should be diluted with the aqueous buffer of choice. Latanoprostene bunod has a solubility of approximately 0.33 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method.

Description

Latanoprostene bunod is a nitric oxide-donating prostaglandin F_{2α} (FP) receptor agonist that is converted to latanoprost (free acid) (Item No. 16811) and nitric oxide (NO) *in vivo*.¹ It induces cGMP accumulation in PC12 and HEK293 cells (EC₅₀s = 1.6 and 9.2 μM, respectively). Topical administration of latanoprostene bunod (0.036% solution) reduces intraocular pressure (IOP) in canine and rabbit models of glaucoma. It also decreases IOP in a cynomolgus monkey model of laser-induced ocular hypertension.

Reference

1. Krauss, A.H.P., Impagnatiello, F., Toris, C.B., *et al.* Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F_{2α} agonist, in preclinical models. *Exp. Eye Res.* **93(3)**, 250-255 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/22/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM